Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

Inclusion Criteria:

- NVAF will be defined as the occurrence of 2 or more inpatient or outpatient claims
with ICD-9 427.31 as the diagnosis code at any time in the patient's data history
prior to inclusion

- Patients will be required to have 180 days of enrollment for the assessment of
baseline characteristics

- CHA2DS2-Vasc (C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years; D:
Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease;
A: Age 65-74 years; Sc: Sex category) score ≥2 during the 180 days prior to index
apixaban use baseline period

Exclusion Criteria:

- Patients <18 years of age

- Patients with valvular AF (Atrial fibrillation)

- Pregnancy

- Malignant cancers

- Transient cause of AF

- Patients with VTE (Venous thromboembolism) (pulmonary embolism or DVT (Deep Vein
Thrombosis))

- Patients with major surgery defined as hip or knee replacement

- Prescriptions of OACs (Oral anticoagulants) (apixaban, warfarin, dabigatran,
rivaroxaban) before index date

- Prescription of more than one OAC on the index date

- Patient with any of the events defined in the composite endpoint